Latest News - Atopic Dermatitis

Monday, September 17, 2018

Almirall and Evotec Form Dermatology Research Collaboration

Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debi…

Read the full story

Friday, September 14, 2018

Inaugural World Eczema Day: GlobalSkin Launches International Movement for Eczema Sufferers

To mark the first-ever Atopic Eczema Day, the International Alliance of Dermatology Patient Organizations (IADPO -- also known as GlobalSkin) has launched AltogetherEczema, a new movement to elevate…

Read the full story

Friday, September 14, 2018

First-Ever Molecular Study Shows African American Skin Reacts Differently to AD

African Americans are known to have greater treatment challenges with atopic dermatitis than European Americans and require higher doses of some medications to get relief, and now a new study suggests…

Read the full story

Thursday, September 06, 2018

Bee Venom May Help Treat Eczema

Bee venom and its major component, melittin, may be effective treatments for atopic dermatitis, according to a British Journal of Pharmacology study. Through studies conducted in mice and in human …

Read the full story

Tuesday, September 04, 2018

JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharma

JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to …

Read the full story

Thursday, August 23, 2018

Wake Forest Researchers: #2 in Probiotic Advancement

Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the bod…

Read the full story

Tuesday, August 14, 2018

Burt’s Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen

Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a s…

Read the full story

Thursday, July 26, 2018

Link Between Diet and Skin Disease Takes Center Stage at Summer AAD

Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looki…

Read the full story

Friday, July 20, 2018

Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officer

Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for ov…

Read the full story

Thursday, July 19, 2018

Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitis

Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development …

Read the full story

Wednesday, July 18, 2018

AD Takes Big Toll on QOL

Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, s…

Read the full story

Sunday, May 27, 2018

Severe AD Linked to CV Risk in Large Trial

Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke an…

Read the full story

Thursday, May 17, 2018

Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meeting

Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic …

Read the full story

Wednesday, May 16, 2018

Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescents

DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with…

Read the full story

Monday, May 07, 2018

Study Seeks to Harness the Power of Probiotics to Treat Eczema

A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria th…

Read the full story
Load More